ImVisioN Therapeutics starts Phase I clinical trial of IVN201 against cat dander allergy and raises CHF 4.6 M
ImVisioN Therapeutics AG announced that it has enrolled the first patient for a Phase I clinical study of its lead product IVN201, an immunotherapeutic product for cat dander allergy. The Company also announced the closing of a Series A Financing round of CHF 4.6 M, allowing the clinical development of IVN201. The financing round was led by Aravis Venture Associates AG and involved the participation of the founding investor Nextech Venture and private individuals.
The primary objective of this first human clinical study on ImVisioN’s lead product IVN201 for the treatment of cat dander allergies will be product safety, but the study will also assess several efficacy parameters. The first patient has been enrolled for this placebo controlled, double blind trial, conducted at the University Hospital in Zurich, Switzerland. The study will include a total of 20 patients allergic to cat dander and is expected to complete in the second quarter of 2009.
Most read news
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.